IN BRIEF: Immupharma moves step closer to Lupazor phase three trial

Immupharma PLC - London-based pharmaceutical company - Confirms that its partner company Avion Pharmaceuticals has received a positive response from the US Food & Drug Administration in its bid to begin a phase three trial of its Lupazor treatment. The two firms have partnered to develop Lupazor, used to treat systemic lupus erythematosus, a potentially life-threatening autoimmune disease.

"We continue to acknowledge the FDA's support following constructive meetings and feedback this year with our partner Avion," says Immupharma Chief Operating Officer Tim Franklin.

"Immupharma and Avion are fully committed to commencing the Lupuzor phase 3 trial in Lupus patients this year."

Current stock price: 8.84 pence, up 6.5% on Thursday

Year-to-date change: down 34%

By Will Paige; willpaige@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Immupharma